Published in final edited form as:

Biochem Biophys Res Commun. 2007 October 12; 362(1): 5–10.

The Receptor Protein Tyrosine Phosphatase (RPTP) β/ζ is Expressed in Different Subtypes of Human Breast Cancer

Pablo Perez-Pinera^{1,*}, Olivia Garcia-Suarez^{2,3,*}, Primitiva Menendez-Rodriguez², J. Mortimer⁴, Y. Chang¹, A. Astudillo^{2,3,§}, and T.F. Deuel^{1,§,¶}

¹ *The Scripps Research Institute, La Jolla, California*

² *Hospital Universitario Central de Asturias, Oviedo, Spain*

³ *Instituto Universitario de Oncologia del Principado de Asturias*

⁴ *Moore's Cancer Center, University of California San Diego, San Diego, California, USA*

Abstract

Increasing evidence suggests mutations in human breast cancer cells that induce inappropriate expression of the 18kDa cytokine pleiotrophin (PTN, *Ptn*) initiate progression of breast cancers to a more malignant phenotype. Pleiotrophin signals through inactivating its receptor, the Receptor Protein Tyrosine Phosphatase (RPTP) β/ζ , leading to increased tyrosine phosphorylation of different substrate proteins of RPTP β/ζ , including β -catenin, β -adducin, Fyn, GIT1/Cat-1, and P190RhoGAP. PTN signaling thus has wide impact on different important cellular systems. Recently, PTN was found to activate Anaplastic Lymphoma Kinase (ALK) through the PTN/RPTP β/ζ signaling pathway; this discovery potentially is very important, since constitutive ALK activity of nucleophosmin (NPM)-ALK fusion protein is causative of anaplastic large cell lymphomas, and, activated ALK is found in other malignant cancers. Recently ALK was identified in each of 63 human breast cancers from 22 subjects. We now demonstrate that RPTP β/ζ is expressed in each of these same 63 human breast cancers that previously were found to express ALK and in 10 additional samples of human breast cancer. RPTP β/ζ furthermore was localized not only in its normal association with the cell membrane but also scattered in cytoplasm and in nuclei in different breast cancer cells and, in the case of infiltrating ductal carcinomas, the distribution of RPTP β/ζ changes as the breast cancer become more malignant. The data suggest that the PTN/RPTP β/ζ signaling pathway may be constitutively activated and potentially function to constitutively activate ALK in human breast cancer.

¶ Address correspondence to: Thomas F. Deuel, M.D. The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037. Tel. 858.784.7923. Fax. 858.784.7977. Email: tfdeuel@scripps.edu.

*These authors contributed equally to this work.

§These authors contributed equally to this work.

¹Y. Chang, M. Zuka, P. Perez-Pinera, A. Astudillo, J. Mortimer, J.R. Berenson, Z. Wang, and T.F. Deuel. Inappropriate Expression of Pleiotrophin (PTN) Stimulates Breast Cancer Progression Through Secretion of PTN and PTN-dependent Remodeling of the Tumor Microenvironment. In Press.

²P. Perez-Pinera, W. Zhang, Y. Chang, J.A. Vega and T.F. Deuel. Anaplastic Lymphoma Kinase (ALK) is Activated Through the Pleiotrophin (PTN)/Receptor Protein Tyrosine Phosphatase (RPTP) β/ζ Signaling Pathway: An "Alternative Mechanism of Receptor Tyrosine Kinase (RTK) Activation". Submitted.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

Pleiotrophin (PTN, *Ptn*) is a cytokine that has important roles in development and differentiation of different cells [1,2]. Pleiotrophin is expressed in different human cancers [3–11], and recently, PTN was identified in different subtypes of human breast cancers [12–14]. Targeting of constitutive PTN signaling in human breast cancers that inappropriately express *Ptn* by a dominant negative PTN reverses their malignant phenotype both *in vitro* and *in vivo* [15]. These studies suggest constitutive PTN signaling in human breast cancers may have an important place in the pathogenesis of human breast cancers.

To address the mechanism through which inappropriate expression of PTN may stimulate progression of breast cancer, mouse mammary tumor virus (MMTV) promoter-driven *Ptn* expressed in MMTV-Polyoma Virus Middle T antigen (*PyMT*)-*Ptn* transgenic mice were analyzed and shown to induce rapid growth of morphologically identified foci of “scirrhous” carcinoma, to extensively remodel the microenvironment, and to induce tumor angiogenesis in the breast cancers of MMTV-*PyMT*-*Ptn* mice, supporting directly the conclusion that inappropriate expression of *Ptn* promotes breast cancer progression in mice; the data linked the consequences of constitutive PTN signaling directly with progression of mouse breast cancers to a phenotype closely resembling a most malignant form of human cancer (Chang et al. In Press)¹; this study also linked the critical importance of secretion of PTN to the critical features of tumor angiogenesis and remodeling of the tumor microenvironment needed to support aggressive breast cancers.

Pleiotrophin signals by inactivating its receptor, the Receptor Protein Tyrosine Phosphatase (RPTP) β/ζ [16,17]; the loss of the tyrosine phosphatase activity of RPTP β/ζ in PTN-stimulated cells leaves tyrosine kinases that target the same sites normally dephosphorylated by RPTP β/ζ free to phosphorylate these same sites, thereby increasing levels of tyrosine phosphorylation of the different substrates of RPTP β/ζ . The downstream targets of the PTN/RPTP β/ζ signaling pathway and thus the substrates of RPTP β/ζ include β -catenin [16], β -adducin [18,19], Fyn [20], GIT1/Cat-1 [21], and P190RhoGAP [22], proteins critical to functions of different cellular systems. PTN through the PTN/RPTP β/ζ signaling pathway thus appears to have a wide impact on the function of PTN-stimulated cells. It is suggested that PTN through the PTN/RPTP β/ζ signaling pathway regulates diverse systems to coordinately influence cell function, a suggestion supported by the recent demonstration that PTN stimulates an epithelial to mesenchymal transition (EMT) in PTN-stimulated cells.

Recently, we demonstrated that Anaplastic Lymphoma Kinase (ALK) is activated through the PTN/RPTP β/ζ signaling pathway (Perez-Pinera et al. Submitted)² and not through the direct interaction of PTN with ALK, as recently suggested [23–25]. Thus, ALK is activated through an Alternative Mechanism of Receptor Tyrosine Kinase (RTK) Activation that is dependent on enforced dimerization and inactivation of RPTP β/ζ .

ALK is a receptor protein tyrosine kinase of the insulin receptor superfamily [26] known to have an essential role in normal development; however, ALK was first discovered as the constitutive active nucleophosmin (NPM)-ALK fusion protein that results from of the (2;5) (p23;q35) chromosomal translocation; NPM-ALK is the oncoprotein that initiates anaplastic large cell lymphomas. We also recently demonstrated that ALK is highly expressed in each of 63 samples of human breast cancer of different subtypes from 22 subjects and furthermore, that the subcellular location and patterns of ALK expression in these different breast cancers differs significantly from its pattern of expression in normal breast tissues [27]. These studies appear to be important, since they suggest that ALK may be activated through the constitutively activated PTN/RPTP β/ζ signaling pathway in breast cancers that inappropriately express *Ptn*.

To pursue the significance of these findings and the possibility that RPTP β/ζ is expressed in these same breast cancers that express ALK, we have now analyzed the expression of RPTP β/ζ and its distribution in human breast cancers by immunohistochemistry.

Methods

Immunohistochemistry

Breast cancer tissue arrays (Catalog number CC08-01-005) were obtained from Cybrdi (Frederick, Maryland). Tissue samples were obtained from the Tissue Bank of the Principado de Asturias.

Tissue slides were deparaffinized (2 $\times$ 10min) in xylene, and hydrated (2 $\times$ 10min) with 100% 95% (2 $\times$ 10min), (1 $\times$ 10min) 90%, (1 $\times$ 10min) 70% ethanol and distilled water (10 min). The slides were then incubated in antigen retrieval solution (Trypsin 0.05%, CaCl₂ 0.1% pH 7.8) for 20 minutes at 37°C and then for 10 minutes at room temperature in a humidified chamber as previously described [28]. Endogenous peroxidase was quenched by incubating the sections with 3% hydrogen peroxide for 5 minutes and the tissues were permeabilized by incubating the samples in Tris-buffered saline (TBS, 10 mM Tris pH 7.6, 150 mM NaCl) with 1% Triton X-100 for 30 minutes. Non-specific binding of the antibodies was reduced by incubating the sections for 30 minutes in a blocking solution containing 2% bovine calf serum, 2% goat serum, 1% BSA, 0.1% gelatin, 0.1% Triton X-100, 0.05% Tween 20 in 10 mM PBS, pH 7.2. The sections were incubated overnight with anti-RPTP β/ζ antibodies (BD Biosciences, La Jolla, CA) diluted 1:100 in PBS pH 7.2, 1% BSA, 0.1% gelatin overnight. The slides were then washed with permeabilization solution (2 $\times$ 10min), incubated with SuperPicTure polymer from Zymed for 30 minutes or the Envision secondary antibody-conjugated polymer from Dako, washed in PBS (2 $\times$ 3min), and developed with DAB provided with the in the SuperPicTure kit Zymed. The slides were rinsed in distilled water 10 min and dehydrated with 70% (1 $\times$ 10min), 90% (1 $\times$ 10min), 95% (2 $\times$ 10min), 100% ethanol (2 $\times$ 10min), and cleared in xylene (2 $\times$ 10min), mounted, observed with a Nikon TE2000U microscope coupled with a Confocal Cell Imaging CARV system, and photographed.

Slides with breast cancers from mouse mammary tumor virus (MMTV)-Polyoma Middle T antigen (PyMT) mice were used as positive control for RPTP β/ζ expression. Samples from MMTV-PyMT mice in which primary antibodies were omitted were used as negative control.

The tumor staging we used as follows:

<u>Tumor staging</u>	
Grade I: 3–5 points	
Grade II: 6–7 points	
Grade III: 8–9 points	
<u>Tubule formation:</u>	
More than 75% of the tumor	1
From 10–75% of the tumor	2
Less than 10% of the tumor	3
<u>Nuclear pleomorphism:</u>	
Small and regular nuclei	1
Moderate increase in nuclear size	2
Marked pleomorphism or nucleolus	3
<u>Mitotic index:</u>	
0–8 mitosis per 10 fields	1
9–16 mitosis per 10 fields	2
More than 17 mitosis per field	3

Results

Expression of RPTP β / ζ was tested in 63 samples of human breast cancer from 22 subjects using immunohistochemistry. The histological phenotypes of the breast cancers studied included infiltrating duct carcinomas, infiltrating lobular carcinomas, medullary carcinomas, mucinous adenocarcinomas, intraductal carcinomas, comedocarcinoma, and Paget's disease. RPTP β / ζ was expressed in all breast cancer samples analyzed (Figure 1) and in normal tissue (Figure 1, B). RPTP β / ζ was expressed in the breast cancer cells themselves, but importantly, RPTP β / ζ also was expressed in the carcinoma associated fibroblast within the breast cancers.

To assess the relative levels of expression of RPTP β / ζ protein, the levels of its expression were scored according to the intensity of immunoreactivity observed using light microscopy and a scale of 1 (low) to 3 (high). The results demonstrated that 75% of the infiltrating ductal carcinomas and 75% of the infiltrating lobular carcinomas expressed low but readily detectable levels of RPTP β / ζ whereas 100% of the medullary carcinomas, 100% of the mucinous carcinomas, and 100% of the intraductal carcinomas express moderate levels of RPTP β / ζ . Interestingly, 80% of the cases of Paget's disease were found to express high levels of RPTP β / ζ (Figure 2). The results also demonstrated that the subcellular localization of RPTP β / ζ is not homogeneous in any of the breast cancers studied, in contrast to the expression of RPTP β / ζ in normal breast tissues. As example, in Paget's disease of the breast, RPTP β / ζ expression was also found in the nuclei (Figure 1, H, arrows).

To develop a better understanding of the subcellular location of RPTP β / ζ , we used ten biopsies from human breast cancers stained using immunohistochemistry with anti-RPTP β / ζ antibodies (Figure 3). The results confirmed that RPTP β / ζ is expressed in ductal carcinomas, in lobular carcinomas, in mucinous carcinomas, and in medullary carcinomas. In the ductal carcinomas, nuclear staining was found in each of the grades of increasing malignancy of infiltrating ductal carcinomas from grades I to III. However, cytoplasmic expression that is prominent in I and II is lost in the most aggressive grade III infiltrating ductal carcinoma. These results suggest that possibly different isoforms of RPTP β / ζ may be expressed in different types of tumors and that changes in the expression pattern of RPTP β / ζ are associated with tumor progression to higher grades of malignancy. The data also suggest the possibility that RPTP β / ζ that has been inactivated through the PTN-enforced dimerization may be processed and appear in different stages of degradation.

In addition, other patterns of expression of RPTP β / ζ were seen in subtypes of breast cancers. Apocrine carcinomas express RPTP β / ζ in an unequal cytoplasmic and nuclear staining (Figure 4 A) whereas mucinous carcinomas express RPTP β / ζ in a mixed nuclear and cytoplasmic pattern (Figure 4 B).

Discussion

We recently demonstrated that ALK is a substrate of RPTP β / ζ and that the PTN-dependent inactivation of RPTP β / ζ is a mechanism through which ALK is activated (Perez-Pinera et al. Submitted)². This mechanism of activation of ALK is unique; it is independent of the classically described direct interaction of a growth factor with its cognate receptor tyrosine kinase (RTK). We also demonstrated that ALK is expressed in each of 63 human breast cancers taken from 22 subjects, suggesting the possibility that constitutive activation of ALK by the PTN/RPTP β / ζ signaling pathway may stimulate progression of human breast cancers. In studies in progress, we also have identified PTN and midkine (MK) also known to signal through RPTP β / ζ [29] in human breast cancers, in further support of the possibility that ALK may be activated through the PTN(MK)/RPTP β / ζ signaling pathway.

In these studies it is demonstrated that RPTP β/ζ is expressed in each of the breast cancer samples studied [30]. It is furthermore demonstrated that the distribution of RPTP β/ζ in each of the subtypes of human breast cancer examined differs from that found in normal breast epithelium and furthermore, the distribution of RPTP β/ζ in infiltrating ductal carcinomas changes as the breast cancers of this subtype become increasingly aggressive.

The demonstration that PTN, RPTP β/ζ , and ALK are expressed in human breast cancers is consistent with the hypothesis that ALK may be activated through the PTN/RPTP β/ζ signaling pathway and activated ALK may function as a potent oncogenic protein in the pathogenesis of human breast cancer.

Acknowledgements

This is manuscript number 18956 from the Scripps Research Institute. This work was supported by grant CA84400 from The National Institutes of Health. The Instituto Universitario de Oncología del Principado de Asturias IUOPA is supported by Cajastur and RTICC funds. The MEM core laboratory is supported by Sam and Rose Stein Endowment Fund. Pablo Perez-Pinera was supported by grant 2 T32 DK007022-26 from the National Institutes of Health. Yunchao Chang was supported by Skaggs training grant. We thank Maria Jose Rodriguez-Arguello for her assistance in the preparation of the samples.

References

1. Li YS, Milner PG, Chauhan AK, Watson MA, Hoffman RM, Kodner CM, Milbrandt J, Deuel TF. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. *Science* 1990;250:1690–1694. [PubMed: 2270483]
2. Deuel TF, Zhang N, Yeh HJ, Silos-Santiago I, Wang ZY. Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. *Arch Biochem Biophys* 2002;397:162–171. [PubMed: 11795867]
3. Vacherot F, Caruelle D, Chopin D, Gil-Diez S, Barritault D, Caruelle JP, Courty J. Involvement of heparin affinal regulatory peptide in human prostate cancer. *Prostate* 1999;38:126–136. [PubMed: 9973098]
4. Soulie P, Heroult M, Bernard I, Kerros ME, Milhiet PE, Delbe J, Barritault D, Caruelle D, Courty J. Immunoassay for measuring the heparin-binding growth factors HARP and MK in biological fluids. *J Immunoassay Immunochem* 2002;23:33–48. [PubMed: 11848100]
5. Zhang L, Mabuchi T, Satoh E, Maeda S, Nukui H, Naganuma H. Overexpression of heparin-binding growth-associated molecule in malignant glioma cells. *Neurol Med Chir (Tokyo)* 2004;44:637–643. [PubMed: 15684595]discussion 644–635
6. Wu H, Barusevicius A, Babb J, Klein-Szanto A, Godwin A, Elenitsas R, Gelfand JM, Lessin S, Seykora JT. Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. *J Cutan Pathol* 2005;32:125–130. [PubMed: 15606670]
7. Souttou B, Juhl H, Hackenbruck J, Rockseisen M, Klomp HJ, Raulais D, Vigny M, Wellstein A. Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. *J Natl Cancer Inst* 1998;90:1468–1473. [PubMed: 9776412]
8. Klomp HJ, Zernial O, Flachmann S, Wellstein A, Juhl H. Significance of the expression of the growth factor pleiotrophin in pancreatic cancer patients. *Clin Cancer Res* 2002;8:823–827. [PubMed: 11895915]
9. Jager R, List B, Knabbe C, Souttou B, Raulais D, Zeiler T, Wellstein A, Aigner A, Neubauer A, Zugmaier G. Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients. *Br J Cancer* 2002;86:858–863. [PubMed: 11953815]
10. Jager R, Noll K, Havemann K, Pfluger KH, Knabbe C, Rauvala H, Zugmaier G. Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell lines. *Int J Cancer* 1997;73:537–543. [PubMed: 9389569]
11. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. *Cancer Lett* 2004;204:127–143. [PubMed: 15013213]
12. Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG. Midkine and pleiotrophin expression in normal and malignant breast tissue. *Cancer* 1994;74:1584–1590. [PubMed: 7520350]

13. Riegel AT, Wellstein A. The potential role of the heparin-binding growth factor pleiotrophin in breast cancer. *Breast Cancer Res Treat* 1994;31:309–314. [PubMed: 7533562]
14. Wellstein A, Fang WJ, Khatri A, Lu Y, Swain SS, Dickson RB, Sasse J, Riegel AT, Lippman ME. A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. *J Biol Chem* 1992;267:2582–2587. [PubMed: 1733956]
15. Zhang N, Zhong R, Wang ZY, Deuel TF. Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant. *J Biol Chem* 1997;272:16733–16736. [PubMed: 9201975]
16. Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M, Deuel TF. Pleiotrophin signals increased tyrosine phosphorylation of beta catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. *Proc Natl Acad Sci U S A* 2000;97:2603–2608. [PubMed: 10706604]
17. Fukada M, Fujikawa A, Chow JP, Ikematsu S, Sakuma S, Noda M. Protein tyrosine phosphatase receptor type Z is inactivated by ligand-induced oligomerization. *FEBS Lett*. 2006
18. Pariser H, Herradon G, Ezquerro L, Perez-Pinera P, Deuel TF. Pleiotrophin regulates serine phosphorylation and the cellular distribution of {beta}-adducin through activation of protein kinase C. *Proc Natl Acad Sci U S A* 2005;102:12407–12412. [PubMed: 16116087]
19. Pariser H, Perez-Pinera P, Ezquerro L, Herradon G, Deuel TF. Pleiotrophin stimulates tyrosine phosphorylation of beta-adducin through inactivation of the transmembrane receptor protein tyrosine phosphatase beta/zeta. *Biochem Biophys Res Commun* 2005;335:232–239. [PubMed: 16105548]
20. Pariser H, Ezquerro L, Herradon G, Perez-Pinera P, Deuel TF. Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: Regulation of tyrosine phosphorylation of Fyn by pleiotrophin. *Biochem Biophys Res Commun* 2005;332:664–669. [PubMed: 15925565]
21. Kawachi H, Fujikawa A, Maeda N, Noda M. Identification of GIT1/Cat-1 as a substrate molecule of protein tyrosine phosphatase zeta/beta by the yeast substrate-trapping system. *Proc Natl Acad Sci U S A* 2001;98:6593–6598. [PubMed: 11381105]
22. Tamura H, Fukada M, Fujikawa A, Noda M. Protein tyrosine phosphatase receptor type Z is involved in hippocampus-dependent memory formation through dephosphorylation at Y1105 on p190 RhoGAP. *Neurosci Lett*. 2006
23. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. *J Biol Chem* 2002;277:14153–14158. [PubMed: 11809760]
24. Bowden ET, Stoica GE, Wellstein A. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. *J Biol Chem* 2002;277:35862–35868. [PubMed: 12107166]
25. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, Wellstein A. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. *J Biol Chem* 2001;276:16772–16779. [PubMed: 11278720]
26. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. *J Cell Physiol* 2004;199:330–358. [PubMed: 15095281]
27. Perez-Pinera P, Chang Y, Astudillo A, Mortimer J, Deuel TF. Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. *Biochem Biophys Res Commun*. 2007
28. Perez-Pinera P, Garcia-Suarez O, Prieto JG, Germana A, Ciriaco E, del Valle ME, Vega JA. Thymocyte depletion affects neurotrophin receptor expression in thymic stromal cells. *J Anat* 2006;208:231–238. [PubMed: 16441567]
29. Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M. A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. *J Biol Chem* 1999;274:12474–12479. [PubMed: 10212223]
30. Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. *J Biol Chem* 1992;267:25889–25897. [PubMed: 1464602]

Figure 1. Expression of RPTPβ/ζ in different human breast cancers

A. Infiltrating ductal carcinoma. **B.** Normal breast tissue. **C.** Infiltrating lobular carcinoma. **D.** Infiltrating ductal carcinoma (papillary pattern). **E.** Medullary carcinoma. **F.** Mucinous adenocarcinoma. **G.** Intraductal carcinoma. **H.** Paget's disease.

Figure 2. Levels of expression of RPTP β/ζ in different human breast cancers

The levels of expression of ALK were quantified using light microscopy and scored in a scale from 1 to 3. The results demonstrated that 75% of the infiltrating ductal carcinomas and 75% of the infiltrating lobular carcinomas expressed low levels of RPTP β/ζ whereas 100% of the medullary carcinomas, 100% of the mucinous carcinomas, and 100% of the intraductal carcinomas express moderate levels of RPTP β/ζ . Interestingly, 80% of the cases of Paget's disease were found to express high levels of ALK and the single sample of comedocarcinoma only weakly expressed RPTP β/ζ .

Figure 3. Levels and pattern of expression of RPTP β/ζ in infiltrating ductal carcinomas
Immunohistochemistry for RPTP β/ζ in grade I (top panels), grade II (middle panels), and grade III (bottom panels). Nuclear staining was observed in all grades whereas the cytoplasmic expression was lost in the highest grade. Magnification: $\times 20$ on the left panels, $\times 40$ on the right panels.

Figure 4. Patterns of expression of RPTPβ/ζ in different carcinomas

A, unequal cytoplasmic and nuclear staining in an uncommon variant of apocrine carcinoma associated to androgen receptors. **B**, nuclear and cytoplasmic staining in a mucinous carcinoma. Magnification: ×40.